Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 15, 1998Blood

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

View Full Paper
Ask AI
Bookmark
Share

Authors

BCB. CoiffierHôpital Lyon SudCHCorinne HaïounUniversité Claude Bernard Lyon 1NKNicolas KettererHirslanden Clinique Bois-Cerf

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Coiffier et al. (1998) studied this question.

synapsesocial.com/papers/6a01bd86bd6301933f5cb71ahttps://doi.org/10.1182/blood.v92.6.1927
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD201994 · 1,948 citations
  2. 2Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non‐Hodgkin's lymphoma1995 · 7 citations
  3. 3Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)1988 · 583 citations
  4. 4A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]1994 · 6,335 citations
  5. 5Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.1995 · 105 citations